Related Experiment Video
Updated: May 12, 2026
07:32
Preparation and Characterization of Individual and Multi-drug Loaded Physically Entrapped Polymeric Micelles
Published on: August 28, 2015
The I-Tribe Community Pharmacy Practice Model: professional pharmacy unshackled.
Greg L Alston1, Jennifer A Waitzman
1School of Pharmacy, Wingate University, 515 N. Main St., Wingate, NC 28174, USA. galston@wingate.edu
Journal of the American Pharmacists Association : Japha
|April 11, 2013
Summary
Pharmacists can leverage technology to offer primary care services online, creating a disruptive innovation. The I-Tribe model enables direct patient connections, expanding access to care and creating new revenue streams for pharmacies.
Area of Science:
- Health Services Research
- Pharmacy Practice
- Health Informatics
Background:
- Community pharmacy practice has focused on sustaining innovations, improving dispensing efficiency but not creating new service demands.
- Pharmacists possess clinical skills and are uniquely positioned to address the gap in primary medical care access.
Purpose of the Study:
- To describe a disruptive innovation model for pharmacists to deliver primary care services.
- To outline a Web-based delivery model leveraging technology for enhanced pharmacy practice.
Main Methods:
- Conceptualization of the I-Tribe Community Pharmacy Practice Model.
- Utilizing a secure, interactive Web presence to connect pharmacists and patients.
Main Results:
- The I-Tribe model represents a disruptive innovation for the primary care market.
- This model overcomes geographic limitations, connecting pharmacists directly with patients.
Conclusions:
- The I-Tribe model can foster a market for pharmacist professional services.
- It expands access to primary medical care and generates new revenue for community pharmacies.
- Enables pharmacists to function as envisioned by professional leaders through entrepreneurial innovation.
Related Concept Videos
01:26Pharmaceutical Poisoning: Potential Scenarios
Pharmaceutical poisoning can occur through various channels, impacting an estimated 2 million hospitalized patients in the U.S. annually with serious adverse drug responses. These scenarios encompass both therapeutic uses, such as drug toxicity, where even standard dosages can lead to severe central nervous system depression, and non-therapeutic exposures, including accidental ingestion by children, and environmental and occupational exposures.Unintentional poisonings often involve exploratory...
01:20Pharmacokinetic Models: Overview
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal assumptions,...
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal assumptions,...
01:06Three-Compartment Open Model
The three-compartment open model is a pharmacokinetic model used to describe the distribution and elimination of drugs following extravascular administration. It comprises a central compartment representing the plasma and two peripheral compartments. The highly perfused peripheral compartment represents organs and tissues with a rich blood supply, such as the liver, kidneys, and lungs. The scarcely perfused peripheral compartment represents tissues with lower blood supply, such as adipose...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
01:26Drug Administration and Therapy Phases: Overview
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
01:27Pharmacodynamic Models: Overview
Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...